Which PARP inhibitor do you recommend for maintenance therapy in BRCA mutated ovarian cancer after primary chemotherapy and why?

Given the abundance of both efficacy and safety data available for Olaparib in this setting, I use Olaparib for maintenance therapy in BRCA+ ovarian cancer patients after primary chemotherapy. The 5-year PFS data from SOLO-1, confirming sustained benefit beyond the end of treatment, further speaks t...

Either olaparib or niraparib. I most commonly start with olaparib, as this has the most favorable toxicity profile. If not tolerated even after dose adjustments, I would consider switching to niraparib.

Use the one you are comfortable using. They are otherwise equally as efficacious.